{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:10:56Z","timestamp":1785247856586,"version":"3.55.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\u03b1-Thalassemia is a severe inherited hemoglobin (Hb) disorder with limited curative options for patients with transfusion dependency, lacking suitable donors. We report, to our knowledge, the first-in-human application of lentiviral vector\u2013mediated \u03b1-globin gene therapy in a girl aged 14 years with transfusion-dependent HbH disease (--SEA\/\u03b1CS\u03b1). Autologous CD34+ hematopoietic stem and progenitor cells were mobilized, collected, and genetically modified ex vivo using the lentiviral vector (Lenti-HBA) to restore \u03b1-globin expression, then reinfused after busulfan conditioning. The patient achieved engraftment within 3 weeks and started to be free of transfusions from the fourth week onward. In the last year of follow-up (months 12-24), the average Hb level remained at \u223c90 g\/L without transfusion support, with HbA accounting for &amp;gt;85% of total Hb. Vector copy numbers were stable, and no evidence of clonal dominance, insertional mutagenesis, or replication-competent lentivirus was detected. Adverse events (AEs) were limited to expected busulfan-related toxicities, including grade 2 menstrual irregularity and ovarian failure (serious AE). Despite cessation of chelation therapy, iron overload progressed minimally, and no cardiac iron deposition occurred. Immune recovery, growth, and development were preserved. This case demonstrates the feasibility, safety, and durable efficacy of lentiviral \u03b1-globin gene therapy as a potential curative treatment for transfusion-dependent \u03b1-thalassemia. This trial was registered at www.clinicaltrials.gov as NCT05851105.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019280","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T10:58:58Z","timestamp":1779879538000},"page":"5153-5160","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Successful gene therapy for transfusion-dependent \u03b1-thalassemia: a case report"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7818-9942","authenticated-orcid":false,"given":"Xiaolin","family":"Yin","sequence":"first","affiliation":[{"name":"1Department of Hematology, The 923rd Hospital of the Joint Logistics Support Force of the People\u2019s Liberation Army, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2391-2702","authenticated-orcid":false,"given":"Linxia","family":"Qian","sequence":"additional","affiliation":[{"name":"2BGI, Shenzhen, China"},{"name":"3BGI Hemogen Therapeutic, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyi","family":"Dong","sequence":"additional","affiliation":[{"name":"2BGI, Shenzhen, China"},{"name":"3BGI Hemogen Therapeutic, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[{"name":"2BGI, Shenzhen, China"},{"name":"3BGI Hemogen Therapeutic, Shenzhen, China"},{"name":"4BGI Research, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Zhou","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The 923rd Hospital of the Joint Logistics Support Force of the People\u2019s Liberation Army, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Yang","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The 923rd Hospital of the Joint Logistics Support Force of the People\u2019s Liberation Army, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiping","family":"Liao","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The 923rd Hospital of the Joint Logistics Support Force of the People\u2019s Liberation Army, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haigang","family":"Sun","sequence":"additional","affiliation":[{"name":"2BGI, Shenzhen, China"},{"name":"3BGI Hemogen Therapeutic, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglian","family":"Guo","sequence":"additional","affiliation":[{"name":"2BGI, Shenzhen, China"},{"name":"3BGI Hemogen Therapeutic, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinru","family":"Zeng","sequence":"additional","affiliation":[{"name":"2BGI, Shenzhen, China"},{"name":"3BGI Hemogen Therapeutic, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilin","family":"Zou","sequence":"additional","affiliation":[{"name":"2BGI, Shenzhen, China"},{"name":"3BGI Hemogen Therapeutic, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Ye","sequence":"additional","affiliation":[{"name":"2BGI, Shenzhen, China"},{"name":"3BGI Hemogen Therapeutic, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"He","sequence":"additional","affiliation":[{"name":"2BGI, Shenzhen, China"},{"name":"3BGI Hemogen Therapeutic, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Yao","sequence":"additional","affiliation":[{"name":"2BGI, Shenzhen, China"},{"name":"3BGI Hemogen Therapeutic, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6539-7975","authenticated-orcid":false,"given":"Wenjie","family":"Ouyang","sequence":"additional","affiliation":[{"name":"2BGI, Shenzhen, China"},{"name":"3BGI Hemogen Therapeutic, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The 923rd Hospital of the Joint Logistics Support Force of the People\u2019s Liberation Army, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[{"name":"2BGI, Shenzhen, China"},{"name":"3BGI Hemogen Therapeutic, Shenzhen, China"},{"name":"5College of Life Sciences, University of Chinese Academy of Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"20","key":"2026072809364548000_bib1","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMra1404415","article-title":"The \u03b1-thalassemias","volume":"371","author":"Piel","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2026072809364548000_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/03630269.2024.2432899","article-title":"Diagnosis and treatment of alpha thalassemia major","volume":"49","author":"Winger","year":"2025","journal-title":"Hemoglobin"},{"issue":"2","key":"2026072809364548000_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.hoc.2022.12.004","article-title":"The clinical phenotypes of alpha thalassemia","volume":"37","author":"Lal","year":"2023","journal-title":"Hematol Oncol Clin North Am"},{"key":"2026072809364548000_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1196\/annals.1345.004","article-title":"Alpha-thalassemia: Hb H disease and Hb Barts hydrops fetalis","volume":"1054","author":"Chui","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"2026072809364548000_bib5","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood-2002-07-1975","article-title":"Hemoglobin H disease: not necessarily a benign disorder","volume":"101","author":"Chui","year":"2003","journal-title":"Blood"},{"issue":"5","key":"2026072809364548000_bib6","doi-asserted-by":"crossref","first-page":"a011742","DOI":"10.1101\/cshperspect.a011742","article-title":"Clinical manifestations of \u03b1-thalassemia","volume":"3","author":"Vichinsky","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"5","key":"2026072809364548000_bib7","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood.V89.5.1762","article-title":"The unusual pathobiology of hemoglobin constant spring red blood cells","volume":"89","author":"Schrier","year":"1997","journal-title":"Blood"},{"issue":"7","key":"2026072809364548000_bib8","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.22033","article-title":"Hematological characteristics and effective screening for compound heterozygosity for Hb constant spring and deletional \u03b1+ -thalassemia","volume":"86","author":"Uaprasert","year":"2011","journal-title":"Am J Hematol"},{"issue":"1","key":"2026072809364548000_bib9","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13023-020-01429-1","article-title":"Non-deletional alpha thalassaemia: a review","volume":"15","author":"Kalle Kwaifa","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"2026072809364548000_bib10","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1056\/NEJMoa1010174","article-title":"Heterogeneity of hemoglobin H disease in childhood","volume":"364","author":"Lal","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"2026072809364548000_bib11","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1111\/bjh.16809","article-title":"Fetal haemoglobin H-Constant Spring disease: a role for intrauterine management","volume":"190","author":"Luewan","year":"2020","journal-title":"Br J Haematol"},{"key":"2026072809364548000_bib12","volume-title":"Guidelines for the Management of \u03b1-Thalassaemia","year":"2023"},{"issue":"17-18","key":"2026072809364548000_bib13","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1089\/hum.2023.138","article-title":"Gene therapy for hemoglobinopathies","volume":"34","author":"Lidonnici","year":"2023","journal-title":"Hum Gene Ther"},{"issue":"5","key":"2026072809364548000_bib14","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.ymthe.2024.03.005","article-title":"Autologous gene therapy for hemoglobinopathies: From bench to patient's bedside","volume":"32","author":"Locatelli","year":"2024","journal-title":"Mol Ther"},{"issue":"1712","key":"2026072809364548000_bib15","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.58347\/tml.2024.1712c","article-title":"Betibeglogene autotemcel (Zynteglo) for beta thalassemia","volume":"66","year":"2024","journal-title":"Med Lett Drugs Ther"},{"issue":"1702","key":"2026072809364548000_bib16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.58347\/tml.2024.1702d","article-title":"In brief: Casgevy for beta thalassemia","volume":"66","year":"2024","journal-title":"Med Lett Drugs Ther"},{"issue":"suppl 1","key":"2026072809364548000_bib17","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.1182\/blood-2024-206807","article-title":"First-in-human study of autologous HBA2-edited CD34+ hematopoietic stem and progenitor cells in alpha-thalassemia with constant spring mutation","volume":"144","author":"Wang","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2026072809364548000_bib18","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1007\/s11427-024-2820-9","article-title":"Lentiviral vectors for gene therapy of \u03b1-thalassemia","volume":"68","author":"Xu","year":"2025","journal-title":"Sci China Life Sci"},{"issue":"10","key":"2026072809364548000_bib19","doi-asserted-by":"crossref","first-page":"102362","DOI":"10.1016\/j.xcrm.2025.102362","article-title":"Lentiviral vectors for hematopoietic stem cell gene therapy restore \u03b1-globin expression in \u03b1-thalassemia red blood cells","volume":"6","author":"Segura","year":"2025","journal-title":"Cell Rep Med"},{"issue":"10","key":"2026072809364548000_bib20","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/17474086.2021.1977116","article-title":"Improving outcomes and quality of life for patients with transfusion-dependent \u03b2-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies","volume":"14","author":"Taher","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"2026072809364548000_bib21","doi-asserted-by":"crossref","first-page":"101155","DOI":"10.1016\/j.omtm.2023.101155","article-title":"Drug product attributes predict clinical efficacy in betibeglogene autotemcel gene therapy for \u03b2-thalassemia","volume":"31","author":"Whitney","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"2026072809364548000_bib22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jcyt.2024.09.001","article-title":"The role of the conditioning regimen for autologous and ex vivo genetically modified hematopoietic stem cell-based therapies: recommendations from the ISCT stem cell engineering committee","volume":"27","author":"Oved","year":"2025","journal-title":"Cytotherapy"},{"issue":"9","key":"2026072809364548000_bib23","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41375-018-0200-3","article-title":"A non-myeloablative conditioning approach for long-term engraftment of human and mouse hematopoietic stem cells","volume":"32","author":"Du","year":"2018","journal-title":"Leukemia"},{"issue":"5577","key":"2026072809364548000_bib24","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1126\/science.1070104","article-title":"Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning","volume":"296","author":"Aiuti","year":"2002","journal-title":"Science"},{"key":"2026072809364548000_bib25","doi-asserted-by":"crossref","first-page":"104136","DOI":"10.1016\/j.exphem.2023.12.001","article-title":"Ex vivo hematopoietic stem cell expansion technologies: recent progress, applications, and open questions","volume":"130","author":"Meaker","year":"2024","journal-title":"Exp Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/14\/5153\/2534580\/blooda_adv-2025-019280-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/14\/5153\/2534580\/blooda_adv-2025-019280-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:36:56Z","timestamp":1785245816000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/14\/5153\/568740\/Successful-gene-therapy-for-transfusion-dependent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":25,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2026,7,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019280","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,28]]},"published":{"date-parts":[[2026,7,20]]}}}